What Is Tirzepatide?
Tirzepatide is a synthetic dual agonist peptide that simultaneously activates two key metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Originally developed by Eli Lilly, it represents a significant advance in incretin-based pharmacology and has been one of the most intensively researched peptide compounds of the early 2020s.
Mechanism of Action
By co-activating GLP-1R and GIPR, tirzepatide engages complementary pathways involved in glucose homeostasis and energy balance. GLP-1R activation stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and promotes satiety via central nervous system pathways. GIPR activation also enhances glucose-dependent insulin secretion and may exert additional effects on adipose tissue function and energy expenditure. The combination of these two mechanisms is hypothesised to produce greater metabolic benefits than either receptor alone.
Research Context
Tirzepatide received FDA approval for type 2 diabetes management in 2022 under the brand name Mounjaro, and subsequently for chronic weight management under the name Zepbound. In the research community, it is studied as a model compound for dual incretin receptor pharmacology, metabolic disease mechanisms, and the role of GIP in obesity biology. Published Phase 3 clinical trial data from the SURPASS and SURMOUNT programmes demonstrated substantial reductions in HbA1c and body weight in research subjects.
Research Areas
Active research areas for tirzepatide include dual incretin pharmacology, adipose tissue biology, non-alcoholic steatohepatitis (NASH), cardiovascular risk reduction, polycystic ovary syndrome (PCOS), obstructive sleep apnoea, and the comparative efficacy of dual versus single agonist approaches in metabolic disease. It is also studied as a reference compound in research into next-generation triple agonists such as retatrutide.
Research Considerations
Tirzepatide is a 39-amino acid synthetic peptide with a fatty diacid moiety attached via a linker for albumin binding, which extends its half-life to approximately 5 days. It is supplied in lyophilised form and requires reconstitution with bacteriostatic water before use in research protocols. Storage at -20°C is recommended for long-term stability. Researchers should note the dual-receptor pharmacology when interpreting experimental results, particularly in models designed to isolate GLP-1R-specific effects.
Where to Source Tirzepatide in Europe
Peptifly supplies Tirzepatide in 5mg and 10mg lyophilised vials, independently tested for 99%+ purity by a third-party laboratory. We dispatch from EU-based fulfilment centres with temperature-controlled packaging. Browse our catalogue at peptifly.com/shop.
Frequently Asked Questions
What is the difference between tirzepatide and semaglutide?
Semaglutide is a single GLP-1 receptor agonist, whereas tirzepatide is a dual GLP-1/GIP receptor agonist. Clinical data suggest tirzepatide produces greater reductions in body weight and HbA1c than semaglutide in head-to-head comparisons, which is attributed to the additive or synergistic effects of dual receptor activation.
Is tirzepatide approved for clinical use?
Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management), and has also received approval in the EU and UK. Peptifly supplies tirzepatide strictly for research and laboratory use only.
Where can I buy tirzepatide in Europe?
Peptifly supplies tirzepatide vials with EU dispatch and independent purity verification for research purposes. Order at peptifly.com/shop.
Disclaimer: All peptides sold by Peptifly are strictly for research and laboratory use only. This article is for informational purposes only.